Feifei Yang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2089796/publications.pdf

Version: 2024-02-01

13	350	840776 11	1125743 13
papers	citations	h-index	g-index

13	13	13	612
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Next-generation of selective histone deacetylase inhibitors. RSC Advances, 2019, 9, 19571-19583.	3.6	83
2	A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nature Communications, 2018, 9, 3726.	12.8	53
3	Optimization of 2-(3-(arylalkyl amino carbonyl) phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone derivatives as potent antitumor growth and metastasis agents. European Journal of Medicinal Chemistry, 2014, 80, 340-351.	5.5	41
4	Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer. Neoplasia, 2014, 16, 665-677.	5.3	35
5	Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities against Tumor Growth and Metastasis. Journal of Medicinal Chemistry, 2014, 57, 9357-9369.	6.4	30
6	Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities. Molecules, 2019, 24, 2569.	3.8	22
7	A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities. Organic and Biomolecular Chemistry, 2016, 14, 1727-1735.	2.8	17
8	The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker. Chemistry and Biodiversity, 2020, 17, e1900427.	2.1	17
9	Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities. Future Medicinal Chemistry, 2020, 12, 655-672.	2.3	14
10	Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, <scp>LW</scp>479, by downâ€regulating <scp>EGFR</scp> expression. British Journal of Pharmacology, 2015, 172, 3817-3830.	5.4	13
11	A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling. Science China Life Sciences, 2017, 60, 202-214.	4.9	12
12	Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities. Molecules, 2020, 25, 717.	3.8	11
13	Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities. MedChemComm, 2019, 10, 1828-1837.	3.4	2